Introgen Therapeutics, Inc. (fka INGNQ)

[biomanbaba]

PGS it seems your theory about the status of T301 is a
RED HERRING. They simply havent found the last patient yet.
unless you are willing to believe the 12-13-04 SEC filing contains a bald face lie. I find that really hard to believe
given Mr Hutts background:
Introgen Therapeutics, Inc. (ticker: ingn, exchange: NASDAQ) News Release - 8/24/04


--------------------------------------------------------------------------------
Introgen Appoints Peter Barton Hutt to Board of Directors; Former FDA Chief Counsel Brings Additional Regulatory and Corporate Experience

AUSTIN, Texas, Aug 24, 2004 (PRNewswire-FirstCall via COMTEX) -- Introgen Therapeutics, Inc. announced today the appointment of Peter Barton Hutt to its Board of Directors. Mr. Hutt, former chief counsel for the Food and Drug Administration (FDA), has participated in drafting most major FDA legislation considered by Congress during the past forty years including the Orphan Drug Act of 1983, the Prescription Drug User Fee Act of 1992, and the Food and Drug Administration Modernization Act of 1997. Mr. Hutt is currently a partner in the Washington, D.C. law firm of Covington & Burling specializing in food and drug law.

"I have always regarded Introgen as an exciting company with a great future. I look forward to working with my colleagues to achieve the Company's goals of bringing novel cancer therapies to the market," said Mr. Hutt.

David G. Nance, CEO of Introgen said, "We are pleased that Peter Hutt is joining our board. His accomplishments in FDA regulatory law and his experience serving as a director of companies registering new classes of therapies provide Introgen with valuable perspectives at an opportune time, as the company moves Advexin toward commercialization."

Mr. Hutt graduated from Yale College and Harvard Law School and obtained a Master of Laws degree in Food and Drug Law from NYU Law School. Mr. Hutt served as Chief Counsel for the Food and Drug Administration during 1971-1975. He is the co-author of the casebook used to teach food and drug law throughout the country. He teaches a full course on this subject each year at Harvard Law School and has taught the same course at Stanford Law School. Mr. Hutt has been a member of the Institute of Medicine since it was founded in 1971. He serves on academic and venture capital advisory boards. He has also served on a number of corporate boards, including IDEC Pharmaceuticals (now Biogen Idec), a company which pioneered the first monoclonal antibody, Rituxan(R) (rituximab), for a cancer indication. He currently serves on the Panel on the Administrative Restructuring of the National Institutes of Health. Out of more than 40,000, he was named by The Washingtonian magazine as one of Washington's 50 best lawyers and as one of Washington's 100 most influential people; by the National Law Journal as one of the 40 best health care lawyers in the United States; and by European Counsel as the best FDA regulatory specialist in Washington, D.C. Business Week has referred to Mr. Hutt as the "unofficial dean of Washington food and drug lawyers."

In addition to Mr. Hutt's prestigious law career in which he argued the only case on public intoxication ever considered by the United States Supreme Court, he has published extensively on food and drug law, alcohol and drug abuse and health and safety laws. He has testified before Congress some 80 times. He is editor-in-chief of the Guide to U.S. Food Labeling Law and editor of the Electronic Book of Harvard Law School Student Papers on Food and Drug Law and serves on the editorial boards of a number of regulatory and law journals.

Peter Barton Hutt joins current board members William Cunningham, Ph.D., former Chancellor of The University of Texas System, Charles Long, Ph.D., former vice-chairman of Citibank and Citicorp, Malcolm Gillis, Ph.D., former president of Rice University and a director of the Federal Reserve Bank of Dallas and Introgen co-founders John Kapoor, Ph.D., president of EJ Financial Enterprises, Inc. and David Nance, CEO Introgen.

Mr. Hutt succeeds Mahendra G. Shah, Ph.D. on Introgen's board of directors, who resigned effective yesterday. Dr. Shah served on Introgen's board since it was founded in 1993 and lent considerable expertise in scientific evaluation, business development and management areas to the company